PHASQ down 99.00% to $0.000001 (PNK): PHASQ stock outlook and next signals

PHASQ stock plunged 99.00% to $0.000001 on the PNK exchange during market hours on 23 Mar 2026, a sharp move driven by microcap illiquidity and legacy Chapter 11 restructuring risks. We see extremely low trading volume at 2,500 shares versus a 50-day average of 22,310.00, and year high at $0.0399. For investors tracking biotechnology microcaps, PhaseBio Pharmaceuticals, Inc. (PHASQ) now trades with effectively zero market cap and wide bid-ask uncertainty in USD.

Market move and trading picture for PHASQ stock

PHASQ stock recorded a one-day change of -99.00%, opening at $0.000001 and trading flat between its day low and day high at $0.000001. Volume was 2,500.00 versus an average volume of 22,310.00, flagging extreme illiquidity. The company shows a previous close of $0.000100, 50-day average price of $0.000236, and 200-day average of $0.000666, indicating a sustained downtrend over multiple time frames.

Low liquidity on the PNK exchange makes price discovery fragile. Investors should expect wide spreads, sporadic fills, and outsized percentage moves from small order sizes when trading PHASQ stock.

Fundamentals and financial ratios affecting PHASQ stock

PhaseBio Pharmaceuticals, Inc. lists EPS at -2.14 and a negative PE metric reflective of losses. Key metrics include cash per share 1.421879072382421, operating cash flow per share -1.612914308518777, and book value per share -3.1646674071776597. Enterprise value is shown as negative in the dataset, and reported market cap is effectively 0.00 USD.

These figures point to a clinical-stage biotech with cash burn and a thin capital base. CurrentRatio is 1.75 and interest coverage is unusually high in the dataset, but these numbers do not remove insolvency or delisting risk given the company’s Chapter 11 legacy and near-zero tradable equity.

Clinical and corporate context driving PHASQ stock news

PhaseBio’s lead candidate, bentracimab (PB2452), is a ticagrelor reversal agent in Phase III trials; other programs include PB1046 and PB6440. The company filed Chapter 11 in October 2022, which remains part of its corporate history and explains persistent investor caution.

Regulatory or trial updates could move sentiment, but absent clear financing or successful restructuring, we expect continued volatility. For company disclosures use the corporate site and public filings source.

Technical indicators and short-term trading signals for PHASQ stock

Technically, PHASQ sits well below its 50-day and 200-day averages (0.000236 and 0.000666 USD). The dataset shows a multi-period decline: 1M -99.00%, 3M -99.50%, 6M -99.90%. Low relative volume (0.11x) suggests price steps are supply-driven rather than demand-driven.

Given these factors, short-term trading is high risk. Momentum traders may avoid PHASQ stock unless they can manage extreme slippage and accept the risk of near-total capital loss.

Meyka AI rating and analyst-style assessment for PHASQ stock

Meyka AI rates PHASQ with a score out of 100: 62.77 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects clinical assets but heavy balance-sheet and liquidity risk.

We highlight specific risks: zero reported market cap, negative book value per share, and very low float trading. Opportunities are binary clinical readouts or restructuring outcomes that could reprice the equity, but probability is uncertain.

Final Thoughts

Key takeaways on PHASQ stock: PhaseBio Pharmaceuticals, Inc. (PHASQ) on the PNK exchange dropped 99.00% to $0.000001 amid extreme thin trading and legacy restructuring concerns. Fundamentals show EPS -2.14, cash per share about 1.42, and negative book value per share, which together imply high insolvency and dilution risk for equity holders. Meyka AI’s forecast model projects a 12-month baseline scenario price of $0.01, which implies an upside of 999900.00% from the current $0.000001; this projection is model-based and not a guarantee. For cautious investors we recommend treating PHASQ stock as a distressed microcap: position sizes should be tiny, orders limited to lit liquidity, and exposure time limited to specific catalyst windows. We will monitor clinical updates, restructuring filings, and liquidity shifts closely. For company disclosures visit the corporate site and social channel source. Meyka AI provides this as one data-driven view through our AI-powered market analysis platform; these grades and forecasts are informational and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.